Johnson & Johnson (NYSE:JNJ) to Issue Quarterly Dividend of $1.34

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Wednesday, July 15th. Stockholders of record on Tuesday, August 25th will be paid a dividend of 1.34 per share on Tuesday, September 8th. This represents a c) dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, August 25th.

Johnson & Johnson has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 64 consecutive years. Johnson & Johnson has a dividend payout ratio of 48.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Johnson & Johnson to earn $12.63 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 42.4%.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $6.30 during mid-day trading on Wednesday, reaching $247.55. 10,539,838 shares of the company’s stock were exchanged, compared to its average volume of 8,428,282. Johnson & Johnson has a one year low of $159.80 and a one year high of $269.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The business’s fifty day simple moving average is $238.18 and its two-hundred day simple moving average is $233.92. The firm has a market capitalization of $595.90 billion, a PE ratio of 28.62, a price-to-earnings-growth ratio of 2.46 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.85 by $0.05. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.02 billion. During the same quarter in the prior year, the business posted $2.77 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently modified their holdings of JNJ. Auto Owners Insurance Co increased its holdings in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $6,924,523,000. Capital World Investors bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $2,005,942,000. Diamant Asset Management Inc. increased its stake in shares of Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after buying an additional 4,454,778 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.